Nominations are now open for the 2027 Merkin Prize in Biomedical Technology! 🏆 This international $400,000 prize recognizes pathbreaking technologies that have improved human health through treatment, diagnosis, or prevention of disease. Learn more: merkinprize.org
Broad Institute
@broadinstitute.org
A multidisciplinary community of researchers with the mission to better understand the roots of disease and narrow the gap between new biological insights and impact for patients. Broadinstitute.org
Mechanistic machine learning for prediction of prime editing outcomes - @broadinstitute.org @hhmi-science.bsky.social www.nature.com/articles/s41...
Mechanistic machine learning for prediction of prime editing outcomes - Nature Biotechnology
OptiPrime incorporates prime-editing biochemistry to predict prime-editing outcomes.
nature.com
OptiPrime, a new AI model from David Liu's lab, helps scientists choose the best pegRNAs to make a desired edit, avoiding slow and costly steps in the lab and streamlining development of gene-editing medicines for rare diseases.
AI model streamlines prime editing
The tool, called OptiPrime, helps researchers more easily determine the best guide RNAs for efficient prime editing, avoiding costly, time-consuming steps in the lab.
broad.io
The Cancer Dependency Map now includes data from dozens of 3D cancer models across 10 cancer types, revealing new dependencies and offering a more comprehensive resource for cancer research.
Cancer Dependency Map now includes next-generation 3D cancer models
Broad scientists expand the DepMap by adding cancer organoids and demonstrate the models’ potential to fuel new discoveries.
broad.io
This Thursday, August 6, at 6PM ET, join us in Cambridge, MA (or online) for a Broad Discovery Series talk with @jbuenrostro.bsky.social: Uncovering Adversity's "Molecular Scars." Register: broadinstitute.swoogo.com/bds2026
Evolution of botulinum neurotoxin serotype X proteases to induce inflammatory cell death in cancer cells - @broadinstitute.org @hhmi-science.bsky.social www.nature.com/articles/s41...
Evolution of botulinum neurotoxin serotype X proteases to induce inflammatory cell death in cancer cells - Nature Biotechnology
Directed evolution of proteases induces targeted, multipathway lytic cell death in cancer cells.
nature.com
New work with Ben Medoff's lab, online now! ADAMTS14 regulates YAP-driven fibroblast activation in IPF. We define an ADAMTS14–collagen V–focal adhesion pathway that contributes to $fibrosis, highlighting ADAMTS14 as a potential therapeutic target. doi.org/10.1093/ajrc...
ADAMTS14 is a Novel Modulator of Fibroblast Mechanoactivation in Pulmonary Fibrosis
AbstractRationale. Yes-associated protein (YAP)-mediated fibroblast mechanoactivation is an important driver of fibrosis in idiopathic pulmonary fibrosis (
doi.org
We're thrilled to announce the Center for Therapeutic Genetics (CTG) — a new collaboration between Broad, Boston Children’s Hospital, and Jackson Laboratory to develop genetic medicines for rare and ultra-rare diseases. (1/3)
Broad Institute, Boston Children’s Hospital, and The Jackson Laboratory launch the Center for Therapeutic Genetics, a non-profit effort to develop genetic medicines for rare and ultra-rare diseases
The new collaboration aims to develop precision medicines, including base and prime editing, to treat patients with rare diseases, using infrastructure and repeatable practices the center will share w...
broad.io
Thank you Broad Institute of MIT and Harvard for this profile. The last 2 years have been an extraordinary moment of creativity and inspiration. If you’re interested in joining us, PM me! We’re building new methods, models and ML tools - we’re recruiting at all levels!
Shaped by a tumultuous childhood, Broad researcher and epigenomic tool-maker @jbuenrostro.bsky.social pivots to studying the biology of stress and adversity and finding new ways to boost resilience.
Shaped by a tumultuous childhood, Broad researcher and epigenomic tool-maker @jbuenrostro.bsky.social pivots to studying the biology of stress and adversity and finding new ways to boost resilience.
A bioengineer shifts his career to explore how life experiences change the body
Shaped by a tumultuous childhood, Jason Buenrostro pivots from technology development to studying the biology of stress and adversity and finding new ways to boost resilience.
broad.io
Join us on Thursday, August 6, at 6PM ET in Cambridge, MA (or online) for a Broad Discovery Series talk with @jbuenrostro.bsky.social: Uncovering Adversity's "Molecular Scars." Register: broadinstitute.swoogo.com/bds2026
We're thrilled to announce that, along with @broadinstitute.org, @bostonchildrens.bsky.social, RARE Hope and partners, JAX was selected for ARPA-H THRIVE Award to advance gene editing platform for pediatric epilepsies and rare CNS diseases. 🧪🧬🧠
The Jackson Laboratory, with the Broad Institute and partners, selected for ARPA-H THRIVE Award to advance gene editing platform for pediatric epilepsies and rare CNS diseases
Pediatric Epilepsies & Rare CNS Gene Editing Platform (PERC) accelerates the development of precision genetic medicines for severe childhood neurologic disease.
jax.org
We're thrilled to announce that a Broad-led consortium of 12 organizations has been selected to receive funding from @arpa-h.bsky.social under its THRIVE program to launch the Pediatric Epilepsies and Rare CNS (PERC) Gene Editing Platform. broad.io/ARPA-H (1/5)
Broad-led consortium receives ARPA-H award to advance gene editing for rare pediatric epilepsy
Twelve organizations spanning gene editing science, clinical medicine, manufacturing, regulatory strategy, and patient advocacy aim to deliver first-in-human trial within three years. div.hero-section...
broad.io
So excited to see this published! This method was a long time in the making and is now being widely used to balance scale with depth, especially for participants where unbiased sequencing approaches are so much more useful than arrays
Broad scientists developed the Blended Genome Exome (BGE) sequencing method, which delivers high-quality, unbiased data at a lower cost than existing gold-standard methods and makes large-scale genetic studies more feasible. @genetisaur.bsky.social
Broad scientists developed the Blended Genome Exome (BGE) sequencing method, which delivers high-quality, unbiased data at a lower cost than existing gold-standard methods and makes large-scale genetic studies more feasible. @genetisaur.bsky.social
Low-cost genome sequencing approach is powering genetics research on mental illness and many other studies
The Blended Genome Exome approach delivers high-quality, unbiased genetic data at a quarter of the cost of the leading sequencing method.
broad.io
New research in Nature Methods from Project Ex Vivo shows AI models learn more from diverse cell states than from scaled datasets alone, a finding that could reshape how therapies are matched to patients. msft.it/6013vgE8l
The 2026 Richard N. Merkin Prize in Biomedical Technology honors Graeme Clark, Erwin Hochmair, Ingeborg Hochmair, Michael Merzenich, and Blake Wilson for developing the modern cochlear implant — a device used by more than 1 million people worldwide.
2026 Merkin Prize in Biomedical Technology awarded to pioneers of the modern cochlear implant
The $400,000 prize honors five researchers who developed the first medical device to generate a human sense through a direct neural interface, a groundbreaking tool used by more than one million peopl...
broad.io
In three new studies, the David Liu lab has optimized key prime editing components (guide pegRNA motifs, reverse transcriptase stability, and delivery via lipid nanoparticles), addressing key bottlenecks that previously impeded its use in animals and human patients.
Scientists improve nearly every aspect of prime editing, moving it closer to treating more genetic diseases
The advances in editing efficiency and delivery are important steps toward in vivo therapeutic prime editing.
broadinstitute.org
Won-Seok Lee @broadinstitute.org, receives the 2026 Nancy S. Wexler Young Investigator Prize, which is awarded annually to an early career researcher whose work reflects the highest caliber of excellence, diligence & creative thinking. Learn more: tinyurl.com/nswprize #curehd #huntingtonsdisease
New research in @natmed.nature.com by @danafarber.bsky.social’s Dr. Suzanne George and Dr. Bradley Bernstein reveals the clinical activity of FGFR inhibition in SDH-deficient GIST. ➡️bit.ly/497QeW8 @broadinstitute.org
My May 20 (next Wednesday!) lecture at Broad: Turns out humans don't have all the answers. There is an untapped opportunity for innovation in medicine by exploring why other species are protected from diseases common in humans. Come and find out more!
Join us in Cambridge, MA (or online) for a Broad Discovery Series talk, “What Animal Superpowers Can Teach Us About Our Own DNA,” on Wednesday, May 20, at 6 pm ET with @elinork.bsky.social of @darwinsark.org. Register: broadinstitute.swoogo.com/Karlsson
Join us in Cambridge, MA (or online) for a Broad Discovery Series talk, “What Animal Superpowers Can Teach Us About Our Own DNA,” on Wednesday, May 20, at 6 pm ET with @elinork.bsky.social of @darwinsark.org. Register: broadinstitute.swoogo.com/Karlsson
NHP-dGTEx V1 derived data is available for download from @GTExPortal. NHP-dGTEx V1 contains 421 Macaque samples (372 RNA-seq and 49 WGS) from 50 subjects and 333 Marmoset samples (314 RNA-seq and 19 WGS) from 20 subjects. bit.ly/4lV8tmI
GTEx Portal
The Genotype-Tissue Expression (GTEx) project is an ongoing effort to build a comprehensive public resource to study tissue-specific gene expression and regulation. Samples were collected from 53 non-...
bit.ly
dGTEx V1 open access data is now available for download from @GTExPortal. dGTEx V1 contains 379 samples from 40 subjects. bit.ly/4rHwa3A #rnaseq
GTEx Portal
The Genotype-Tissue Expression (GTEx) project is an ongoing effort to build a comprehensive public resource to study tissue-specific gene expression and regulation. Samples were collected from 53 non-...
bit.ly
Broad researchers used their single-molecule tracking technology to reveal unexpected patterns of dimerization among EGFR family receptors, shedding light on their role in cancer. Learn more: broad.io/Peng-EGFR
Other mammals have so many abilities that we don't, but which could teach us a lot about health and disease. Join us for what promises to be a talk filled to the brim with great science and super-cute animal pictures!
Have you ever wondered what animal superpowers can teach us about our own DNA? Join us in Cambridge, MA (or online) for a Broad Discovery Series talk on Wednesday, May 20 at 6 pm ET with Elinor Karlsson. Register: broadinstitute.swoogo.com/Karlsson
Excited to share our paper out today in @science.org! We directed high-content, single-cell genetic screens to ask how a disordered adapter protein orchestrates the complex process of T cell activation. (1/4) www.science.org/doi/10.1126/...
Disordered protein LAT encodes relative levels of signaling pathways in T cell activation
The disordered adapter protein linker for activation of T cells (LAT) propagates T cell receptor signaling. To interrogate how LAT coordinates multiple downstream pathways, we developed a single-cell ...
science.org
Have you ever wondered what animal superpowers can teach us about our own DNA? Join us in Cambridge, MA (or online) for a Broad Discovery Series talk on Wednesday, May 20 at 6 pm ET with Elinor Karlsson. Register: broadinstitute.swoogo.com/Karlsson
A new drug candidate designed to slow the progression of prion disease is entering a phase 1 clinical trial. The trial, led by Eric Minikel, codirector of Broad’s Prion Therapeutic Science program, will evaluate a divalent small interfering RNA (siRNA) drug candidate for safety and tolerability.
Clinical trial of a prion disease drug candidate begins enrolling participants
It’s the first time the potential treatment, a small interfering RNA targeting the prion protein, is being tested in humans.
broad.io
Out now in @cp-cellhostmicrobe.bsky.social! In collaboration with Swiss clinicians, we built the largest nasal microbial gene atlas in infants w/ and w/o cystic fibrosis to date (cont.)